Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest DCIS Stories

2014-04-04 23:34:52

Cianna Medical, Inc.: Strut-based breast cancer radiation treatment could expand options for DCIS patients. Aliso Viejo, Calif. (PRWEB) April 03, 2014 Cianna Medical, Inc., a women’s health company, today announced the results of a retrospective study of breast cancer patients with ductal carcinoma in situ (DCIS) treated with SAVI® breast brachytherapy. Researchers reported excellent local control, with recurrence rates that appear to be equivalent to those expected for whole...

2013-10-11 23:19:21

Ductal carcinoma in situ (DCIS), a noninvasive breast cancer that some doctors are now arguing is over-treated, needs to be evaluated according to each woman’s risk, and more research is needed to better evaluate that risk, two Allegheny Health Network oncologists write in the Journal of the National Cancer Institute. DCIS represents up to 25% of new breast cancer diagnosis. Pittsburgh, PA (PRWEB) October 11, 2013 Ductal carcinoma in situ (DCIS), a noninvasive breast cancer that some...

2013-09-18 15:45:20

Results of EORTC trial 10853 appearing in the Journal of Clinical Oncology show that breast conserving treatment combined with radiotherapy reduces the risk of local recurrence in women with ductal carcinoma in situ (DCIS). The incidence of DCIS has been increasing in the past decades, and this has been attributed to increased detection through breast cancer screening using mammograms. In the EORTC study, adjuvant radiotherapy after local excision reduced the incidence of both in situ and...

2013-05-10 16:24:42

REDWOOD CITY, Calif., May 10, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that, effective May 8, 2013, Palmetto GBA, the designated national contractor for its Oncotype DX® breast cancer test, has expanded its coverage policy for all qualified Medicare patients to include patients with ductal carcinoma in situ (DCIS) following the recent publication of the breast cancer test's DCIS Score in the peer-reviewed, Journal of the National Cancer Institute....

2013-05-02 16:30:17

Findings Demonstrate Utility of Oncotype DX® to Guide Radiation Treatment Decision for DCIS Patients and Support Expanded Access and Reimbursement REDWOOD CITY, Calif. and PHILADELPHIA, May 2, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) and the ECOG-ACRIN Cancer Research Group announced today that the Journal of the National Cancer Institute (JNCI) published positive results from their clinical validation study of the Oncotype DX® DCIS Score in patients with...

2012-12-10 08:25:43

REDWOOD CITY, Calif., Dec. 10, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the results from six studies of the Oncotype® DX breast cancer test presented at the 34(th) Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) reinforcing the impact of the test on facilitating better informed treatment decisions in patients with node-negative and node-positive invasive early-stage breast cancer. Additionally, two studies demonstrated the test's cost...

2012-11-29 14:32:03

The combined loss of two tumor suppressor genes, retinoblastoma (RB) and phosphatase and tensin homolog (PTEN) was shown to be strongly associated with progression of DCIS to invasive breast cancer, according to a study published November 28 in the Journal of the National Cancer Institute. Ductal carcinoma in situ (DCIS) is a breast cancer precursor lesion for which there are no established markers defining risk of progression to invasive breast cancer. As a result, the majority of...

2012-11-28 08:30:05

REDWOOD CITY, Calif., Nov. 28, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from six Oncotype® DX breast cancer test studies at the 34(th) Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), taking place December 6-8, 2012 at the Henry B. Gonzalez Convention Center. Presentations include results from evaluations of the Oncotype DX breast cancer test's clinical utility and health economic value in...

2012-04-06 09:25:47

Women with ductal carcinoma in situ (DCIS) have high rates of diagnostic and invasive breast procedures after treatment with breast-conserving surgery (BCS) according to a study published April 5 in the Journal of the National Cancer Institute. Breast-conserving surgery is the most common treatment for ductal carcinoma in situ and has proven to be an effective alternative to mastectomy in most women; however, the necessity for and likelihood of further diagnostic mammograms and invasive...

2012-03-23 11:11:34

Negative surgical margins should be attained for ductal carcinoma in situ (DCIS) patients after breast-conserving surgery (BCS) regardless of radiotherapy, and surgeons should attempt to reach wide negative margins in their first attempt within cosmetic restraint according to a study published March 22 in the Journal of the National Cancer Institute. Margin status is an important predictor of local recurrence regardless of subsequent radiotherapy (RT) for women with DCIS who are treated...